PHARMACEUTICALS: LATEST INTERVIEWS MORE INTERVIEWS

Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."

PHARMACEUTICALS: LATEST ARTICLES

Funding Environment: Life Sciences Enter the Mainstream

April 15, 2021
The past 12 months been transformative for the life science industry in USA and GBR explores how the funding environment has evolved to provide the influx of capital to sustain its innovations.

Turkey Pharmaceuticals: Bringing All Actors Together

June 17, 2020
Industry, university, investors - the two-way bridge to the knowledge gap.

PHARMACEUTICALS: RECENTLY RELEASED PUBLICATIONS

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

Mining in Ontario and Toronto's Global Reach 2021

PARTNER EVENTS